Literature DB >> 8335937

Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA.

B H O'Neil1, Y Kawakami, N P Restifo, J R Bennink, J W Yewdell, S A Rosenberg.   

Abstract

To detect shared human melanoma Ag that are recognized by HLA-A2 restricted, melanoma-specific CTL derived from tumor infiltrating lymphocytes, we have developed a convenient method to insert and express foreign HLA genes capable of presenting Ag on target cell lines. Seventeen melanoma cell lines and 11 nonmelanoma cell lines were infected with recombinant vaccinia virus containing the HLA-A2.1 gene. Infection by the vaccinia virus resulted in expression of functional HLA-A2 molecules on the cell surface of virtually 100% of infected cells within a 3.5-h period. The results showed that 11 of 17 (65%) naturally HLA-A2- melanoma cell lines were specifically lysed by the HLA-A2-restricted, melanoma-specific TIL after infection with the vaccinia-HLA-A2.1 virus. None of the nine human nonmelanoma cell lines tested (three colon cancer, four breast cancer, or two immortalized non-tumor cell lines) or two murine melanoma cell lines were lysed by the HLA-A2-restricted TIL after vaccinia-HLA-A2.1 infection. Coinfection of the vaccinia virus containing the beta 2-microglobulin gene with the vaccinia-HLA-A2.1 virus increased the surface expression of HLA-A2 and subsequent lysis by melanoma-specific tumor infiltrating lymphocytes. With this new method we could extend previous findings demonstrating that shared melanoma Ag recognized by HLA-A2-restricted tumor infiltrating lymphocytes exist among melanoma cells from different patients regardless of HLA type. These Ag represent excellent candidates for the development of vaccines to induce T cell responses for the immunotherapy of patients with melanoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335937      PMCID: PMC2121328     

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

Review 1.  Vaccinia virus expression vectors.

Authors:  B Moss; C Flexner
Journal:  Annu Rev Immunol       Date:  1987       Impact factor: 28.527

2.  Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.

Authors:  Y Kawakami; R Zakut; S L Topalian; H Stötter; S A Rosenberg
Journal:  J Immunol       Date:  1992-01-15       Impact factor: 5.422

3.  The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens.

Authors:  P J Bjorkman; M A Saper; B Samraoui; W S Bennett; J L Strominger; D C Wiley
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

4.  Structure of the human class I histocompatibility antigen, HLA-A2.

Authors:  P J Bjorkman; M A Saper; B Samraoui; W S Bennett; J L Strominger; D C Wiley
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

5.  Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28.

Authors:  P Parham; F M Brodsky
Journal:  Hum Immunol       Date:  1981-12       Impact factor: 2.850

6.  Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens.

Authors:  S S Hom; D J Schwartzentruber; S A Rosenberg; S L Topalian
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-01

7.  Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines.

Authors:  R Zakut; S L Topalian; Y Kawakami; M Mancini; S Eliyahu; S A Rosenberg
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

8.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; P Spiess; R Lafreniere
Journal:  Science       Date:  1986-09-19       Impact factor: 47.728

9.  Identification of human cancers deficient in antigen processing.

Authors:  N P Restifo; F Esquivel; Y Kawakami; J W Yewdell; J J Mulé; S A Rosenberg; J R Bennink
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

10.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.

Authors:  K Itoh; C D Platsoucas; C M Balch
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more
  12 in total

1.  Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.

Authors:  C J Kim; T Prevette; J Cormier; W Overwijk; M Roden; N P Restifo; S A Rosenberg; F M Marincola
Journal:  J Immunother       Date:  1997-07       Impact factor: 4.456

Review 2.  Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".

Authors:  W W Overwijk; N P Restifo
Journal:  Crit Rev Immunol       Date:  2000       Impact factor: 2.214

3.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

Authors:  Y Kawakami; S Eliyahu; C H Delgado; P F Robbins; L Rivoltini; S L Topalian; T Miki; S A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

4.  Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.

Authors:  S L Topalian; L Rivoltini; M Mancini; N R Markus; P F Robbins; Y Kawakami; S A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

5.  An SV40 VP1-derived epitope recognized by CD8+ T cells is naturally processed and presented by HLA-A*0201 and cross-reactive with human polyomavirus determinants.

Authors:  Hephzibah Rani S Tagaram; Alan M Watson; Francois A Lemonnier; Kevin Staveley-O'Carroll; Satvir S Tevethia; Todd D Schell
Journal:  Virology       Date:  2008-04-10       Impact factor: 3.616

Review 6.  T-cell recognition of human melanoma antigens.

Authors:  Y Kawakami; M I Nishimura; N P Restifo; S L Topalian; B H O'Neil; J Shilyansky; J R Yannelli; S A Rosenberg
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-08

7.  Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line.

Authors:  M K Jakobsen; N P Restifo; P A Cohen; F M Marincola; L B Cheshire; W M Linehan; S A Rosenberg; R B Alexander
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1995-05

8.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.

Authors:  N P Restifo; F M Marincola; Y Kawakami; J Taubenberger; J R Yannelli; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1996-01-17       Impact factor: 13.506

9.  Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines.

Authors:  A F Kirkin; T R Petersen; A C Olsen; L Li; P thor Straten; J Zeuthen
Journal:  Cancer Immunol Immunother       Date:  1995-08       Impact factor: 6.968

10.  Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest.

Authors:  P Shamamian; M Mancini; Y Kawakami; N P Restifo; S A Rosenberg; S L Topalian
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.